Skip to main content
Back to feed
HealthSingle-sourceLow
2.1

SK Biopharmaceuticals acquires global rights for U.S.-developed epilepsy drug candidate

SK Biopharmaceuticals has secured global development and commercialization rights for an epilepsy drug candidate from an unnamed U.S. biotechnology firm. The deal expands the company's CNS (central nervous system) portfolio, though financial terms and the specific drug candidate remain undisclosed.

Yonhap EN1 day agoKR, USCredibility 32%View source

Score Breakdown

Mosaic Score2.1
Confidence0.9
Significance0.1
Source credibility0.3

Intelligence Tags

#biotech#pharma#epilepsy#licensing#sk-biopharmaceuticals

Locations

Seoul

Entities

countrycountry
Source

Related signals

8 found